Pharmacologic Optimization of Voriconazole

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycellhave received18 yearsinvasive
  Phrases that lowered it: and safetydrugefficacy andallergiccross over
• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 10 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 32.0% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.2% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 2053 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 461 (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults NCT00855101 · started 2009 · scored riskier than 3% of active trials completed
• A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen NCT03760276 · started 2018 · scored riskier than 1% of active trials completed
• A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients NCT01092832 · started 2010 · scored riskier than 97% of active trials terminated
• MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients NCT02227797 · started 2015 · scored riskier than 70% of active trials completed
• Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) NCT01657201 · started 2012 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.